Personalized medicine

1. | 1
Goldman Hirsh Partners
Expertise, Sourcing, Operation,
Administration
Long-Term
Partnership
Chinese Partner
Knowledge, Resources,
Chinese Market
September 2016
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.
GHP-China
MedTech Hub
A unique collaborative business
platform that will profit from the
huge potential of Personalized
Medicine by synergizing the
complementary capabilities of
its Chinese and Israeli partners in
order to bring the most
advanced health therapies to the
peoples of China and Israel, and
of the world.

2. |
Under Personalized Medicine the patient asks:
Is this treatment going to work for me ?
What is the treatment for this disease ?
2
Not
Personalized medicine encompasses all aspects of treatment, drugs, diagnostics,
information technology and medical devices, all under one vision: the tailoring of
medical treatment to the individual characteristics, needs, and preferences of a
patient during all stages of care, including prevention, diagnosis, treatment, and
follow-up. This approach offers new solutions to medical problems and innovative
ways to implement existing solutions.
Personalized Medicine - The Next Blockbuster
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

3. Selection of optimal therapy and
reduction in trial-and-error
The
Importance
of
Personalized
Medicine
| 3
Provides for better
prevention, not only
better reaction
Helps control and reduce the
overall cost of health care
Increases patient
adherence to treatment
Reveals additional or alternative
uses for drug candidates
Helps avoid adverse
drug reactions
Improves quality of life
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

4. Personalized Medicine in Numbers
$2,452 BILLION
Estimated Global Market
in 2022
$1,007 BILLION
Global Market
in 2014
| 4© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

5. Commercializing Personalized Medicine
| 5
Utilization
of Big Data
Application of
Modern
Technologies
Evaluation of
Academic
Knowledge
Specific
Management
Proficiencies
Understanding
of Medical
Environments
Access to
Large
Advanced
Markets​
The Combined Essentials
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

6. The GHP-China MedTech Hub
| 6
Goldman
Hirsh
Partners Chinese
Partner
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.
Doing Business Together

7. The Investment Opportunity
Personalized medicine,
the future of medical
treatment
| 7
Creating scientific and
commercial synergies
between China and Israel
Raising the overall value of the
MedTech Hub by co-developing
Israeli technologies that are
potentially worth hundreds of
millions of dollars in China and
throughout the world
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

8. Focus on personalized
medicine
| 8
Utilizing GHP’s
fundamentals and
expertise
Technologies that after
initialization can be co-
developed in China
Strategy
Balanced portfolio
Leveraging the capabilities of
the Chinese Partners
Generation of attractive
returns for the stakeholders
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

9. Inception of the MedTech Hub
| 9© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.
The GHP-China MedTech Hub will be raising $40,000,000
in two equal stages.
Inception
GHP
Chinese
Partner
1 st Stage:
$20,000,000

10. Focus on
Personalized
Medicine
| 10
GHP
A unique
business
group
Specializing in the
development,
integration and
commercialization
of biomedical
technologies
Cutting
edge Israeli
technologies
direct from their
source
Proven
experience
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

11. | 11© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.
GHP
Management
Evaluation
and
Selection
R&D Program
Finance
IP
Cooperation
Human
Resources
Advisory
Boards
Supervision
and
Reporting
Risk
Management

12. | 12
GHP Technology Network
Direct Access
Universities
Medical
Centers
Business
Communities
Government
Authorities
Pharmaceutical
Industry
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.
Research
Institutes
Medical
Centers
Private
Initiative

13. In-house Evaluation and Selection
| 13
PoC
Great
Research
Team
Innovative
Technology
Strong IP
Protection
Large
Global
Market
Validated
Proof of
Concept
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.
High ROI

14. Goldman Hirsh Group
Leading Technologies:
| 14
A new concept in targeted
therapy to overcome cancer-
drug resistance
www.tyrnovo.co.il
A molecular diagnostics
company integrating
molecular genomics with
personalized therapeutic
approaches
www.genesort.com
Automated sterile mass-
injection devices for
humans and livestock
www.adst.co.il
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.
A molecular diagnostics
company active in the field
of Women’s Health
www.diagyn.com
Repositioning of failed drugs to
provide personalized treatment
for cancer patients
www.optimacure.com

15. GHP Team
Management
Gil Pogozelich
Ph.D,M.A. Law.
Active Chairman and CEO
Merton Rieck
B.Sc.
BusinessDevelopment Manager
Monica B. Wolmer
CPA.
Chief FinancialOfficer
Hila Dovev David
LL.B.
Internal Legal Counsel
Richie Grunbaum
B.A.
Business and Project Manager
Yehonatan Oren
M.A.
Communications Manager
| 15
Unique Combination of Life Science and Business Advisors
Avi Shachar
B.Sc. Eng., Director
Expert in
Manufacturing
Prof. Izhak Haviv
Specialist in Cancer and
Genome Research
Joshua Oren
Partner, Industrialist
Dubi Diamant
M.A., Director
Expert in Defense
and Security
Arie Lazarovich
Partner, Expert in Clinical Trials
Yigal Erlich
Partner, Specialist in
Hi-Tech and Venture
Capital
Avi Yohanan
B.A., Director
Expert in Business
Strategy
Salomon M. Stemmer
Expert in Cancer Therapy
Itzik Rabinovitz
Specialist in Product
Development
Prof. Ervin Weiss
Partner, Specialist
in Dental Medicine
Prof. Raphael Katan
Specialist in Oncology and Drug
Development
Netanel Katz
Organizational
Psychologist
Prof. Ronnie Levy
Specialist in
Pharmaceutics
Dr. Guy Livnat
Specialist in Pulmonary and
Critical Care Medicine
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

16. The GHP-China MedTech Hub
| 16
The bridge that will improve the health of the peoples of China
and Israel, and of the world
www.goldman-hirsh.com
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved.

17. Disclaimer
© 2016 Goldman Hirsh Partners Ltd. All rightsreserved. | 17
Highly Confidential © Copyright Goldman Hirsh Partners Ltd. All rights reserved. All text, images,
graphics and other materials which are part of this document are subject to copyrights and other
intellectual property rights of Goldman Hirsh Partners Ltd. ("GHP"), and nothing contained herein
may be reproduced for commercial use or distributed, modified or transmitted in any form or by any
means, other than for the specific purpose for which they were provided herein or with the express
written consent of GHP. Nothing in this document may be construed as granting any proprietary
rights of GHP whatsoever. The contents of this document are proprietary to GHP and are highly
confidential. You may not use, disclose, copy or otherwise exploit the contents of this document
without the express prior written authorization of GHP. The contents of this document are disclosed
to recipients of this document solely for the purposes agreed with GHP. This document does not
constitute a legally binding offer or contract nor is it intended to create any legal or binding
commitment upon GHP and it is intended solely as a basis for further discussion between us. This
proposal is provided to you and is of a personal nature and is not to be transferred or assigned to any
other party without GHP’s express written consent. The contents are provided “as is” without any
warranty, express or implied (by statute or otherwise), as to accuracy, satisfactory quality, ownership,
validity or otherwise. While precaution has been taken in the preparation of this document, GHP
assumes no responsibility for errors or omissions. GHP excludes and disclaims all such warranties to
the maximum permitted extent. At the request of GHP, you must return this document and all copies
thereof in your possession or control.